Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR2 | O43614 | 9/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 2/20 | 0.34 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21522306 | 0.91 | HCRTR2 (0.38) | HCRTR2SMN1; SMN2ALDH1A1MAPTHPGD | |
| SCHEMBL30101457 | 0.85 | SMN1; SMN2 (0.40) | HCRTR2SMN1; SMN2ALDH1A1MAPTHSD17B10 | |
| SCHEMBL28530071 | 0.78 | SMN1; SMN2 (0.33) | SMN1; SMN2ALDH1A1MAPTHPGDNPSR1 | |
| SCHEMBL28522218 | 0.76 | SMN1; SMN2 (0.42) | HCRTR2SMN1; SMN2ALDH1A1NPSR1HSD17B10 | |
| SCHEMBL21522575 | 0.74 | ALDH1A1 (0.44) | HCRTR2SMN1; SMN2ALDH1A1MAPTNPSR1 | |
| SCHEMBL3830067 | 0.74 | F2 (0.41) | HCRTR2ALDH1A1POLBL3MBTL1 | |
| SCHEMBL13191752 | 0.73 | GAA (0.40) | SMN1; SMN2ALDH1A1TP53POLB | |
| SCHEMBL3182268 | 0.73 | POLB (0.44) | POLBL3MBTL1 | |
| SCHEMBL3178302 | 0.73 | POLB (0.44) | POLBL3MBTL1 | |
| SCHEMBL3178313 | 0.73 | POLB (0.44) | POLBL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4234551-A2 | PYRIDAZINONES AS PARP7 INHIBITORS | Ribon Therapeutics Inc. (US) | 2023-08-30 | — | — | EP | disclosed |
| US-20230192664-A1 | PYRIDAZINONES AS PARP7 INHIBITORS | ANKURA TRUST COMPANY, LLC, AS COLLATERAL TRUSTEE | 2023-06-22 | — | — | US | disclosed |
| EP-3788040-B1 | PYRIDAZINONES AS PARP7 INHIBITORS | RIBON THERAPEUTICS INC (US) | 2023-04-12 | — | — | EP | disclosed |
| US-11014913-B2 | Pyridazinones as PARP7 inhibitors | RIBON THERAPEUTICS, INC. (US) | 2021-05-25 | — | — | US | disclosed |
| EP-3788040-A1 | PYRIDAZINONES AS PARP7 INHIBITORS | Ribon Therapeutics Inc. (US) | 2021-03-10 | — | — | EP | disclosed |
| US-20210024502-A1 | PYRIDAZINONES AS PARP7 INHIBITORS | ANKURA TRUST COMPANY, LLC, AS COLLATERAL TRUSTEE | 2021-01-28 | — | — | US | disclosed |
| US-10870641-B2 | Pyridazinones as PARP7 inhibitors | RIBON THERAPEUTICS, INC. (US) | 2020-12-22 | — | — | US | disclosed |
| US-20200123134-A1 | PYRIDAZINONES AS PARP7 INHIBITORS | ANKURA TRUST COMPANY, LLC, AS COLLATERAL TRUSTEE | 2020-04-23 | — | — | US | disclosed |
| US-10550105-B2 | Pyridazinones as PARP7 inhibitors | Ribon Therapeutics Inc. (US) | 2020-02-04 | — | — | US | disclosed |
| US-20190330194-A1 | PYRIDAZINONES AS PARP7 INHIBITORS | ANKURA TRUST COMPANY, LLC, AS COLLATERAL TRUSTEE | 2019-10-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210024502-A1 | PYRIDAZINONES AS PARP7 INHIBITORS | PARP2, PARP1, PARP4 | HCRTR2 4717/4885SMN1; SMN2 4309/4885ALDH1A1 1033/4885 |
| US-10550105-B2 | Pyridazinones as PARP7 inhibitors | PARP2, PARP1, PARP4 | HCRTR2 4717/4885SMN1; SMN2 4309/4885ALDH1A1 1033/4885 |
| US-20190330194-A1 | PYRIDAZINONES AS PARP7 INHIBITORS | PARP2, PARP1, PARP4 | HCRTR2 4717/4885SMN1; SMN2 4309/4885ALDH1A1 1033/4885 |
| US-11014913-B2 | Pyridazinones as PARP7 inhibitors | PARP2, PARP1, PARP4 | HCRTR2 4717/4885SMN1; SMN2 4309/4885ALDH1A1 1033/4885 |
| US-10870641-B2 | Pyridazinones as PARP7 inhibitors | PARP2, PARP1, PARP4 | HCRTR2 4717/4885SMN1; SMN2 4309/4885ALDH1A1 1033/4885 |
| US-20230192664-A1 | PYRIDAZINONES AS PARP7 INHIBITORS | PARP2, PARP1, PARP4 | HCRTR2 4717/4885SMN1; SMN2 4309/4885ALDH1A1 1033/4885 |
| US-20200123134-A1 | PYRIDAZINONES AS PARP7 INHIBITORS | PARP2, PARP1, PARP4 | HCRTR2 4717/4885SMN1; SMN2 4309/4885ALDH1A1 1033/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.